925
Views
57
CrossRef citations to date
0
Altmetric
Letters to the Editor

MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia

, , , , , , , , , , , , , , , , , , & show all
Pages 1087-1090 | Received 18 May 2012, Accepted 19 Aug 2012, Published online: 12 Nov 2012

References

  • Zenz T, Gribben JG, Hallek M, . Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 2012;119: 4101–4107.
  • Fangazio M, de Paoli L, Rossi D, . Predictive markers and driving factors behind Richter syndrome development. Expert Rev Anticancer Ther 2011;11:433–442.
  • Rossi D, Spina V, Deambrogi C, . The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 2011;117:3391–3401.
  • Hurlin PJ, Steingrìmsson E, Copeland NG, . Mga, a dual-specificity transcription factor that interacts with Max and contains a T-domain DNA-binding motif. EMBO J 1999;18:7019–7028.
  • Rossi D, Spina V, Cerri M, . Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res 2009;15: 4415–4422.
  • Rossi D, Cerri M, Deambrogi C, . The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009;15:995–1004.
  • Fabbri G, Rasi S, Rossi D, . Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011;208:1389–1401.
  • Rossi D, Bruscaggin A, Spina V, . Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011;118:6904–6908.
  • Rossi D, Rasi S, Fabbri G, . Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012;119:521–529.
  • Rossi D, Fangazio M, Rasi S, . Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012;119:2854–2862.
  • Rinaldi A, Mian M, Kwee I, . Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. Br J Haematol 2011;154:590–599.
  • Zhang W, Kater AP, Widhopf GF 2nd, . B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2010;107:18956–18960.
  • Huh YO, Lin KI, Vega F, . MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. Br J Haematol 2008;142:36–44.
  • Put N, Van Roosbroeck K, Konings P, . Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course. Ann Hematol 2012; 91:863–873.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.